heart disease

Conoidin A is a cell-permeable inhibitor of the T. gondii enzyme peroxiredoxin II (TgPrxII) with nematicidal properties. It covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC50 of 23 μM. It also inhibits hyperoxidation of mammalian PrxI and PrxII (but not PrxIII). Conoidin A has antioxidant, neuroprotective effects and can be used for research on ischaemic heart disease.

Arbutamine (GP 21213) is a novel potent non-selective beta-adrenoceptor agonist with alpha-1-sympathomimetic activity.Arbutamine promotes cardiac stress and increases heart rate, cardiac contractility.Arbutamine can be used to study cardiac stress and coronary artery disease

Cicloprolol hydrochloride is a new potent and selective beta 1-adrenoceptor antagonist with partial agonist activity for the study of coronary heart disease.

(2R,3S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide is an Apelin receptor agonist with an EC50 for Apelin receptors of 0.012 µM.(2R,3S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5- methylpyrimidin-2-yl)butane-2-sulfonamide is used in the treatment of heart failure, atherosclerosis, obesity, diabetes mellitus, amyotrophic lateral sclerosis, coronary artery disease, hypertension, stroke and myocardial infarction.

Pomisartan (BIBR-363) is a small molecule angiotensin type 1 receptor (AT1R) antagonist that is used in the treatment of cardiovascular disease, studying heart failure and hypertensio

Afacifenacin (SMP-986) fumarate is an M3 muscarinic receptor-selective antagonist used in the study of ischemic heart disease, urinary incontinence and cystitis and other disorders.

Oxeladin citrate is a highly potent and effective cough suppressant, which can treat all types of cough of various etiologies. It is not related to opium or its derivatives, so treatment with oxeladin is no risk of addiction. And it has none of the side effects (such as hypnosis, respiratory depression, tolerance, constipation and analgesia) which are present when common antitussives. It can used at every age, as well as in patients with heart disease, since it is high level of safety and a great selectivity to act on the bulbar centre of cough.

Nebivolol hydrochloride (R 065824 hydrochloride) is a cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients.

Trimetazidine dihydrochloride (Vastarel F) can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.

Torsemide (AC-4464) is an anilinopyridine sulfonylurea belonging to the class of loop diuretics. Torsemide has a prolonged duration of action compared to other loop diuretics, is extensively protein bound in plasma and has a relatively long half-life.

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker whose mechanism of action involves antagonizing the Angiotensin 2 Receptor.

Aplodan (creatinol-O-phosphate) exhibits antiischemic and antiarrhythmic capacity and protective action on the cell membrane. Aplodan can be used in research on the ischemic heart or ischemic heart disease with persistent ventricular premature beats.

Tanshinone IIA (Tanshinone B) is a diterpene quinone natural product that targets the protein kinase domain of VEGF/VEGFR2. Tanshinone IIA inhibits angiogenesis and exhibits anti-inflammatory, antioxidant, and therapeutic activities against coronary heart disease.

Betaine (trimethylglycine) is a methyl derivative of glycine first isolated from sugar beets. It has been shown to have potential benefits for fighting heart disease, improving body composition, and helping promote muscle gain and fat loss because of its abilities to promote protein synthesis in the body.

Heptadecanoic acid is a fatty acid of exogenous (primarily ruminant) origin. Many odd length long chain amino acids are derived from the consumption of dairy fats (milk and meat). Heptadecanoic acid constitutes 0.61% of milk fat and 0.83% of ruminant me

Trapidil (Avantrin) is a coronary vasodilator agent. It was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.

Metoprolol Tartrate is a blocker of the cardioselective β-adrenergic receptor.

Bovinic acid ((9Z,11E)-Octadecadienoic acid) is a conjugated linoleic acid with anticancer and anti-atherosclerotic activity and can be used to study coronary heart disease and obesity in the elderly.

Levocarnitine propionate (L-Propionylcarnitine) is a propionyl-coenzyme A (Pro-CoA) derivative with anti-ischemic effects and high affinity for muscle L-carnitine transferase. Levocarnitine propionate enhances substrate oxidation and mitochondrial respiration in the heart of diabetic rats, reduces gastric ulcer area, induces mucosal recovery, and can be used to study acute respiratory distress syndrome and chronic gastric ulcers in Alzheimer's disease.

FR 58664 is a drug to treat heart failure disease.

Butyrylcarnitine is a plasma metabolite that is an indicator of abnormal metabolism due to disease and is used in the diagnosis of heart failure and pancreatic cysts.

Enalapril sodium is used to treat high blood pressure, diabetic kidney disease, and heart failure and can be generally used with a diuretic such as furosemide for heart failure.

Hypoxia inducer-1 (Compound N6) is a NO donor compound that is orally active and activated under hypoxic conditions. It exhibits high selectivity in releasing NO, inhibiting apoptosis, necrosis, and elevated levels of reactive oxygen species (ROS) associated with hypoxia. It modulates vasodilation and shows protective effects in a mouse model of myocardial hypoxic injury, making it useful for coronary heart disease research.

Perindopril (S-9490) is a long-acting ACE inhibitor effective for 24 hours, primarily utilized in the management of high blood pressure, heart failure, or stable coronary artery disease. Available as perindopril arginine (with trade names such as Coversyl and Coversum) or perindopril erbumine (known as Aceon), both formulations are regarded therapeutically equivalent, according to the Australian Government's Pharmaceutical Benefits Scheme—meaning they can be interchanged without clinical effect differences, though their dosing may vary due to distinct molecular weights. Notably, perindopril ranks among the most frequently prescribed ACE inhibitors, thanks to its extensive evidence base supporting its use in patients with hypertension, type 2 diabetes, coronary heart disease, and chronic heart failure. This review highlights perindopril's organoprotective benefits that extend beyond its capacity to lower blood pressure.